UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5094) 5094
Book Chapter (98) 98
Newspaper Article (38) 38
Newsletter (11) 11
Magazine Article (9) 9
Book / eBook (5) 5
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4765) 4765
female (4745) 4745
science & technology (3957) 3957
life sciences & biomedicine (3822) 3822
endometrial cancer (2421) 2421
oncology (2396) 2396
middle aged (2075) 2075
endometrial neoplasms - pathology (1879) 1879
endometrial neoplasms - drug therapy (1848) 1848
aged (1557) 1557
cancer (1516) 1516
obstetrics & gynecology (1443) 1443
adult (1417) 1417
endometrial neoplasms - metabolism (784) 784
neoplasm staging (661) 661
endometrial neoplasms - genetics (655) 655
breast neoplasms - drug therapy (636) 636
cell line, tumor (631) 631
risk factors (628) 628
prognosis (609) 609
care and treatment (584) 584
chemotherapy (575) 575
aged, 80 and over (567) 567
endometrial neoplasms - surgery (553) 553
animals (549) 549
research (534) 534
breast cancer (527) 527
endometrial neoplasms - chemically induced (525) 525
endometrium (521) 521
treatment outcome (517) 517
ovarian cancer (497) 497
obstetrics and gynecology (491) 491
health aspects (482) 482
tamoxifen - adverse effects (478) 478
retrospective studies (474) 474
antineoplastic combined chemotherapy protocols - therapeutic use (456) 456
antineoplastic agents, hormonal - therapeutic use (431) 431
hematology, oncology and palliative medicine (421) 421
analysis (418) 418
tamoxifen - therapeutic use (417) 417
tamoxifen (389) 389
abridged index medicus (385) 385
tumors (385) 385
endometrial carcinoma (383) 383
endometrium - pathology (368) 368
chemotherapy, adjuvant (364) 364
follow-up studies (331) 331
adenocarcinoma - drug therapy (330) 330
immunohistochemistry (328) 328
endometrial neoplasms - epidemiology (326) 326
apoptosis (323) 323
hysterectomy (323) 323
endometrial neoplasms - mortality (316) 316
endometrium - drug effects (312) 312
ovarian neoplasms - drug therapy (312) 312
estrogen (307) 307
mice (302) 302
antineoplastic agents - therapeutic use (298) 298
metastasis (297) 297
drug therapy (291) 291
antineoplastic agents, hormonal - adverse effects (288) 288
adenocarcinoma - pathology (286) 286
endometrial neoplasms - therapy (279) 279
medicine & public health (275) 275
neoplasm recurrence, local - drug therapy (272) 272
endometrial neoplasms - diagnosis (271) 271
gene expression (271) 271
oncology, experimental (267) 267
endometrial neoplasms - radiotherapy (265) 265
surgery (265) 265
survival rate (263) 263
pathology (257) 257
cell proliferation - drug effects (254) 254
proteins (242) 242
cell biology (241) 241
genetic aspects (241) 241
mutation (240) 240
apoptosis - drug effects (239) 239
postmenopause (238) 238
cancer therapies (236) 236
combined modality therapy (235) 235
disease-free survival (233) 233
ovarian neoplasms - pathology (231) 231
development and progression (226) 226
women (225) 225
menopause (221) 221
tumor cells, cultured (218) 218
gynecology (217) 217
male (213) 213
time factors (211) 211
antineoplastic agents - pharmacology (209) 209
gene expression regulation, neoplastic (209) 209
research article (209) 209
carcinoma (204) 204
medical prognosis (204) 204
prospective studies (204) 204
paclitaxel - administration & dosage (201) 201
hormone replacement therapy (198) 198
cervical cancer (195) 195
pregnancy (191) 191
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5026) 5026
Japanese (68) 68
German (57) 57
French (55) 55
Russian (44) 44
Chinese (41) 41
Polish (15) 15
Spanish (15) 15
Italian (14) 14
Bulgarian (13) 13
Portuguese (7) 7
Hebrew (5) 5
Hungarian (4) 4
Czech (3) 3
Swedish (3) 3
Danish (2) 2
Norwegian (2) 2
Bosnian (1) 1
Dutch (1) 1
Romanian (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Current drug targets, ISSN 1389-4501, 11/2015, Volume 16, Issue 12, pp. 1381 - 1403
MicroRNAs (miRNAs) are small single stranded non coding RNA molecules (similar to 22 nucleotides) which impede protein production by directly interacting with... 
Epithelial to mesenchymal transition | Biomarker | Tumor microenvironment | Tumor suppressor | MicroRNAs | MiR-200c | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | MicroRNAs - therapeutic use | Neoplasms - metabolism | Lung Neoplasms - drug therapy | Prostatic Neoplasms - metabolism | Pancreatic Neoplasms - metabolism | Pancreatic Neoplasms - diagnosis | Humans | Lung Neoplasms - metabolism | Endometrial Neoplasms - metabolism | Stomach Neoplasms - metabolism | Male | MicroRNAs - metabolism | Antineoplastic Agents - therapeutic use | Neoplasms - diagnosis | Prostatic Neoplasms - diagnosis | Colorectal Neoplasms - diagnosis | Breast Neoplasms - metabolism | Pancreatic Neoplasms - drug therapy | Biomarkers, Tumor - therapeutic use | Colorectal Neoplasms - drug therapy | Biomarkers, Tumor - metabolism | Female | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Colorectal Neoplasms - metabolism | Prostatic Neoplasms - drug therapy | Stomach Neoplasms - diagnosis | Ovarian Neoplasms - diagnosis | Biomarkers, Tumor - physiology | Stomach Neoplasms - drug therapy | Endometrial Neoplasms - diagnosis | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Animals | Endometrial Neoplasms - drug therapy | Breast Neoplasms - diagnosis | MicroRNAs - physiology | Lung Neoplasms - diagnosis
Journal Article
PloS one, ISSN 1932-6203, 12/2015, Volume 10, Issue 12, pp. e0145754 - e0145754
... clinical response to their primary therapy, nearly half will develop disease recurrence within 18 months and the majority will die from disease recurrence within 5 years... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Endometrial Neoplasms - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Genital Neoplasms, Female - drug therapy | DNA, Neoplasm - blood | Endometrial Neoplasms - genetics | Adult | Female | Neoplasm Recurrence, Local - blood | Ovarian Neoplasms - drug therapy | Genital Neoplasms, Female - genetics | CA-125 Antigen - blood | Ovarian Neoplasms - blood | Genital Neoplasms, Female - blood | Mutation - genetics | Breast Neoplasms - drug therapy | Biomarkers, Tumor - blood | Genital Neoplasms, Female - mortality | Exome - genetics | Breast Neoplasms - genetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Endometrial Neoplasms - drug therapy | Neoplasm Recurrence, Local - genetics | Aged | Biomarkers, Tumor - genetics | DNA, Neoplasm - genetics | Endometrial Neoplasms - blood | Physiological aspects | Prognosis | Biological markers | Genital cancer | Tumors | Plasma | Scanning | Ovarian carcinoma | Fallopian tube | Cancer therapies | Ovarian cancer | Gene sequencing | Computed tomography | Surgery | Quality | Imaging | Endometrium | Deoxyribonucleic acid--DNA | DNA probes | Gynecology | Breast cancer | Patients | Survival | Obstetrics | Medicine | Lead time | Chemotherapy | Surveillance | Womens health | Biomarkers | Diagnostic systems | Mutation | Reproductive system | Uterine cancer | Peritoneum | Cancer | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Cancer chemotherapy and pharmacology, ISSN 1432-0843, 07/2019, Volume 84, Issue 3, pp. 487 - 499
.... While their function in hepatic metabolism of taxanes is well established, expression of these enzymes in solid tumors may play a role in the in situ metabolism of drugs as well, potentially... 
Intratumoral | Ritonavir | Paclitaxel | Docetaxel | CYP | Review | Journal Article | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Taxoids - pharmacology | Humans | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Male | Breast Neoplasms - enzymology | Female | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2C8 - metabolism | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Endometrial Neoplasms - enzymology | Lung Neoplasms - enzymology | Neoplasms - enzymology | Breast Neoplasms - drug therapy | Ovarian Neoplasms - enzymology | Neoplasms - drug therapy | Breast Neoplasms - pathology | Cytochrome P-450 CYP3A - metabolism | Prostatic Neoplasms - enzymology | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Neoplasms - pathology | Antimitotic agents | Protease inhibitors | Proteases | Pharmacy | Cytochrome P-450 | Physiological aspects | Drugstores | Antineoplastic agents | Ovarian cancer | Cytochrome | Enzymes | Cytochrome P450 | Proteinase inhibitors | Taxane | Metabolism | Anticancer properties | Antitumor agents | Lungs | Drug metabolism | Breast | Solid tumors | Taxanes | Prostate | Endometrium | Tumors | Cytochromes P450 | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 08/2017, Volume 123, Issue 16, pp. 3080 - 3087
BACKGROUND Mirvetuximab soravtansine (IMGN853) is an antibody‐drug conjugate that selectively targets folate receptor α (FRα... 
clinical trial | targeted therapy | folate receptor | phase 1 | antibody‐drug conjugate | antibody-drug conjugate | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Humans | Middle Aged | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Vision Disorders - chemically induced | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Hypophosphatemia - chemically induced | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Neoplasms, Glandular and Epithelial - pathology | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Renal Cell - pathology | Maytansine - analogs & derivatives | Keratitis - chemically induced | Maytansine - therapeutic use | Disease Progression | Neoplasms - drug therapy | Maximum Tolerated Dose | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Kidney Neoplasms - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Kidney Neoplasms - drug therapy | Neoplasms - pathology | Cancer patients | Care and treatment | Pharmacokinetics | Health aspects | Analysis | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 12/2015, Volume 33, Issue 34, pp. 4015 - 4022
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2013, Volume 31, Issue 12, pp. 1554 - 1561
Journal Article
Journal Article
Clinical cancer research, ISSN 1557-3265, 08/2013, Volume 19, Issue 18, pp. 5227 - 5239
Purpose: The aim of this study was to identify and validate novel predictive and/or prognostic serum proteomic biomarkers in patients with epithelial ovarian... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Endometrial Neoplasms - mortality | Peritoneal Neoplasms - blood | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Ovarian Neoplasms - mortality | Adenocarcinoma, Clear Cell - blood | Cystadenocarcinoma, Serous - drug therapy | Bevacizumab | Patient Selection | Fallopian Tube Neoplasms - blood | Peritoneal Neoplasms - drug therapy | Adenocarcinoma, Mucinous - blood | Angiogenesis Inhibitors - therapeutic use | Chromatography, Liquid | Adult | Female | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Cystadenocarcinoma, Serous - blood | Antibodies, Monoclonal, Humanized - therapeutic use | Ovarian Neoplasms - blood | Survival Rate | Peritoneal Neoplasms - mortality | Biomarkers, Tumor - blood | Adenocarcinoma, Mucinous - mortality | Validation Studies as Topic | Fallopian Tube Neoplasms - mortality | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Aged | Neoplasm Staging | Endometrial Neoplasms - blood | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | bevacizumab | predictive | ICON7 | proteomics | serum | biomarkers
Journal Article
Gynecologic oncology, ISSN 0090-8258, 11/2018, Volume 151, Issue 2, pp. 337 - 344
Paclitaxel, a microtubule inhibitor, is subject to tumor resistance while treating high-grade serous ovarian and uterine cancer. This study aims to directly... 
Oncology | Life Sciences & Biomedicine | Obstetrics & Gynecology | Science & Technology | Paclitaxel - pharmacology | Apoptosis - drug effects | Tubulin Modulators - pharmacology | Humans | Receptor Protein-Tyrosine Kinases - biosynthesis | Cystadenocarcinoma, Serous - metabolism | Endometrial Neoplasms - metabolism | Ovarian Neoplasms - pathology | Neoplasms, Glandular and Epithelial - metabolism | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | Proto-Oncogene Proteins - biosynthesis | Cystadenocarcinoma, Serous - drug therapy | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Endometrial Neoplasms - genetics | Female | Ovarian Neoplasms - metabolism | Ovarian Neoplasms - drug therapy | Neoplasms, Glandular and Epithelial - pathology | Cell Growth Processes - drug effects | Proto-Oncogene Proteins - genetics | Mice, SCID | Xenograft Model Antitumor Assays | Animals | RNA, Neoplasm - biosynthesis | Receptor Protein-Tyrosine Kinases - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Cell Line, Tumor | RNA, Neoplasm - genetics | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Mice, Inbred NOD | Mice | Cell Cycle - drug effects | Colchicine | RNA | Uterine cancer | Tubulins | Growth | Analysis | Index Medicus
Journal Article